London
· Delayed Price · Currency is GBP · Price in GBX ANGLE Company Description
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally.
The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis.
It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal transition; and CellKeep Slide, a CTC harvesting technology.
In addition, the company offers laboratory services, including enumeration of epithelial and mesenchymal CTC populations; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays.
ANGLE plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use its proprietary pan-cancer next generation sequencing (NGS) panel.
The company was founded in 1994 and is based in Guildford, the United Kingdom.
| Country | United Kingdom |
| Founded | 1994 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 119 |
| CEO | Andrew David Newland |
Contact Details
Address: Surrey Research Park Guildford, GU2 7AF United Kingdom | |
| Phone | 44 14 8334 3434 |
| Website | angleplc.com |
Stock Details
| Ticker Symbol | AGL |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB0034330679 |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Andrew David Newland | Chief Executive Officer |
| Ian Griffiths | Chief Financial Officer |